Therefore, CANTOS (Canakinumab Anti-inflammatory Thrombosis OutcomeStudy) study was designed to confirm the independent role of inflammation inatherosclerosis, and to explore inhibition of IL-1β as a therapeuticoption for coronary artery disease [30]. The gene discussed is IL1B; the disease is coronary artery disorder.